文献速递胸部肿瘤

ADAURA试验辅助奥希替尼治疗切除后EGFR突变IB-IIIA期NSCLC的8年OS探索性更新

Adjuvant Osimertinib in Resected EGFR-Mutated Stage IB-IIIA NSCLC: Exploratory 8-Year Overall Survival Landmark Update from the ADAURA Trial.
PubMed 文献 · J Thorac Oncol · 2026-09-13

ADAURA试验纳入682例切除后EGFR突变IB-IIIA期NSCLC患者,随机接受奥希替尼或安慰剂辅助治疗。本次探索性分析显示,II-IIIA期人群OS HR为0.53(95%CI 0.38-0.75),8年OS率74%对58%;IB-IIIA期人群OS HR为0.52(95%CI 0.39-0.71),8年OS率79%对64%,长期随访进一步证实辅助奥希替尼的生存获益。

要点

  • II-IIIA期8年OS率奥希替尼74% vs 安慰剂58%,OS HR 0.53。
  • IB-IIIA期8年OS率奥希替尼79% vs 安慰剂64%,OS HR 0.52。
  • EGFR Ex19del和L858R的OS HR分别为0.45和0.72,各亚组均见获益。

核心结论

  • 在切除后EGFR突变IB-IIIA期NSCLC中,辅助奥希替尼较安慰剂显示出长期OS获益,8年OS率在II-IIIA期和IB-IIIA期人群均高于安慰剂。

研究设计与样本

  • ADAURA为全球III期随机对照试验,682例患者随机接受奥希替尼或安慰剂辅助治疗。
  • 本次为事后探索性长期OS分析,纳入全部随机患者,更新了558例计划最终OS分析时存活患者中431例的生存数据。

主要发现

  • II-IIIA期人群OS HR为0.53(95%CI 0.38-0.75),8年OS率奥希替尼74% vs 安慰剂58%,中位随访92.0 vs 68.5个月。
  • IB-IIIA期人群OS HR为0.52(95%CI 0.39-0.71),8年OS率奥希替尼79% vs 安慰剂64%,中位随访93.3 vs 79.6个月。
  • EGFR Ex19del和L858R突变的OS HR分别为0.45(95%CI 0.29-0.68)和0.72(95%CI 0.46-1.11)。
  • 各亚组均观察到奥希替尼的OS获益。

关键数值与推荐

  • II-IIIA期:OS HR 0.53(95%CI 0.38-0.75),8年OS率74% vs 58%。
  • IB-IIIA期:OS HR 0.52(95%CI 0.39-0.71),8年OS率79% vs 64%。
  • Ex19del:OS HR 0.45(95%CI 0.29-0.68);L858R:OS HR 0.72(95%CI 0.46-1.11)。

临床怎么用

  • 对于切除后EGFR突变IB-IIIA期NSCLC,辅助奥希替尼的长期OS数据支持其作为标准辅助治疗选择。
  • 不同EGFR突变亚型(Ex19del与L858R)均可见OS获益趋势,支持按突变类型整体评估辅助奥希替尼获益。

局限性

  • 本次分析为事后探索性分析,并非预设的主要终点分析。
  • 部分患者缺乏额外随访,其生存时间沿用计划最终OS分析数据截止日的删失值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: In ADAURA, adjuvant osimertinib improved disease-free survival (DFS) and overall survival (OS) compared with placebo in patients with resected epidermal growth factor receptor (EGFR)-mutated stage IB-IIIA NSCLC. We report a post hoc exploratory analysis of long-term OS after adjuvant treatment completion. METHODS: Patients (N = 682) were randomized to osimertinib or placebo until recurrence, treatment completion, or discontinuation. Updated survival data were collected from 431 of 558 patients alive at the planned final OS analysis (data cutoff [DCO], January 27, 2023) through yearly follow-up until the current DCO (May 4, 2026) or from accessible records or information from the last contact date after January 27, 2023. Patients without additional follow-up remained censored, with survival time unchanged from the planned final OS analysis DCO (n = 127). This exploratory long-term OS analysis was conducted in all randomized patients. RESULTS: At the current DCO, in the stage II-IIIA population, the OS hazard ratio (HR) was 0.53 (95% confidence interval [CI]: 0.38-0.75); the 8-year OS rates were 74% (osimertinib) versus 58% (placebo); the median follow-up was 92.0 versus 68.5 months. In the stage IB-IIIA population, the OS HR was 0.52 (95% CI: 0.39-0.71); the 8-year OS rates were 79% (osimertinib) versus 64% (placebo); the median follow-up was 93.3 versus 79.6 months. The OS HRs according to EGFR Ex19del and L858R mutations were 0.45 (95% CI: 0.29-0.68) and 0.72 (95% CI: 0.46-1.11), respectively. An OS benefit with osimertinib was observed across subgroups. CONCLUSION: With the longest OS from a global phase III adjuvant trial in EGFR-mutated stage IB-IIIA NSCLC, these additional long-term results further characterize the established survival benefit of adjuvant osimertinib. CLINICAL TRIAL INFORMATION: ADAURA (NCT02511106).

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Wu YL, Majem M, John T, et al. Adjuvant Osimertinib in Resected EGFR-Mutated Stage IB-IIIA NSCLC: Exploratory 8-Year Overall Survival Landmark Update from the ADAURA Trial. J Thorac Oncol. 2026. PMID: 42732874. doi:10.1016/j.jtho.2026.104179

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。